Posted by Michael Wonder on 30 May 2018
TherapeuticsMD announces FDA approval of TX-004HR: Imvexxy (oestradiol vaginal inserts), the lowest dose vaginal oestrogen product approved for the treatment of moderate to severe dyspareunia due to menopause
30 May 2018 - Imvexxy's applicator-free self-administration was developed with the woman in mind.
TherapeuticsMD today announced that the US FDA has approved Imvexxy (oestradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, due to menopause.
Imvexxy is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg representing the lowest approved dose of vaginal oestradiol available.
